Abstract
Based on the Ph 3 IMpower133 trial, atezo + CE was FDA/EMA-approved in 2019 for first-line (1L) treatment (tx) of ES-SCLC. We explored clinical characteristics, tx patterns and early outcomes of the IMpower133 regimen in the RW setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
